Leap Therapeutics Future Growth

Future criteria checks 0/6

Leap Therapeutics is forecast to grow earnings and revenue by 6.4% and 87.8% per annum respectively while EPS is expected to grow by 17.9% per annum.

Key information

6.4%

Earnings growth rate

17.9%

EPS growth rate

Biotechs earnings growth42.7%
Revenue growth rate87.8%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:5MC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262-58-67-494
12/31/2025N/A-56-56-534
12/31/2024N/A-68-64-594
9/30/2024N/A-65-55-55N/A
6/30/2024N/A-60-50-50N/A
3/31/2024N/A-53-47-47N/A
12/31/2023N/A-81-45-44N/A
9/30/2023N/A-81-48-46N/A
6/30/2023N/A-82-50-48N/A
3/31/2023N/A-86-51-50N/A
12/31/2022N/A-55-49-49N/A
9/30/20220-53-47-47N/A
6/30/20221-49-43-43N/A
3/31/20221-42-38-38N/A
12/31/20212-41-35-35N/A
9/30/20212-37-30-30N/A
6/30/20212-32-29-29N/A
3/31/20212-29-31-31N/A
12/31/20202-38-26-26N/A
9/30/20201-39-26-26N/A
6/30/20201-40-26-26N/A
3/31/20200-42-24-24N/A
12/31/2019N/A-33-27-27N/A
9/30/2019N/A-24-28-28N/A
6/30/2019N/A-22-29-29N/A
3/31/2019N/A-21-27-27N/A
12/31/2018N/A-23-26-26N/A
9/30/2018N/A-31-25-25N/A
6/30/2018N/A-31N/A-20N/A
3/31/2018N/A-31N/A-21N/A
12/31/2017N/A-30N/A-22N/A
9/30/2017N/A-29N/A-23N/A
6/30/2017N/A-30N/A-28N/A
3/31/2017N/A-30N/A-28N/A
12/31/2016N/A-26N/A-25N/A
9/30/2016N/A-23N/A-21N/A
6/30/2016N/A-19N/A-15N/A
3/31/2016N/A-14N/A-11N/A
12/31/2015N/A-12N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 5MC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 5MC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 5MC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 5MC is forecast to have no revenue next year.

High Growth Revenue: 5MC is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 5MC's Return on Equity is forecast to be high in 3 years time


Discover growth companies